Caso Clínico: CANCER DE VEJIGA Enfermedad metastásica - page 34

Efficacy<br />Responses to Atezolizumab by PD-L1 IC Subgroup

Presented By Robert Dreicer at 2016 ASCO Annual Meeting

vigor 210: Phase II study

(Cohort 2 pretreated)

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,24,25,26,27,28,29,30,31,32,33 35,36,37,38,39,40,41,42,43,...44